| P2093 | author name string | Chi-Un Pae | |
| P2860 | cites work | Beyond the monoaminergic hypothesis: neuroplasticity and epigenetic changes in a transgenic mouse model of depression | Q24629465 |
| | Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date | Q27004490 |
| | Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine | Q28240140 |
| | A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline | Q28286878 |
| | Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials | Q28297824 |
| | Triple Reuptake Inhibitors: A Premise and Promise | Q28972234 |
| | Agomelatine and hepatotoxicity: implications of cumulated data derived from spontaneous reports of adverse drug reactions. | Q30662760 |
| | Novel melatonin-based therapies: potential advances in the treatment of major depression | Q34186242 |
| | A benefit-risk assessment of agomelatine in the treatment of major depression | Q34207131 |
| | Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study | Q34526245 |
| | Placebo-controlled trial of agomelatine in the treatment of major depressive disorder | Q34562100 |
| | A regulatory Apologia--a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants | Q34594119 |
| | Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial | Q34655680 |
| | Chronic treatment with agomelatine or venlafaxine reduces depolarization-evoked glutamate release from hippocampal synaptosomes | Q34878452 |
| | Chronobiology of mood disorders | Q38126091 |
| | Manipulating melatonin in managing mood | Q38126092 |
| | Getting depression clinical practice guidelines right: time for change? | Q38126094 |
| | Neurogenesis along the septo-temporal axis of the hippocampus: are depression and the action of antidepressants region-specific? | Q38131239 |
| | The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study | Q38448630 |
| | The efficacy of agomelatine in previously-treated depressed patients | Q46453816 |
| | Publication bias and outcome reporting bias: agomelatine as a case example | Q48288020 |
| | Antidepressant efficacy of agomelatine versus SSRI/SNRI | Q57738189 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 443-447 | |
| P577 | publication date | 2014-01-08 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Agomelatine: a new option for treatment of depression? | |
| P478 | volume | 15 | |